VA awards $33.9K for SUCRAID 8500 UNT/ML SOLN, highlighting a 5-day delivery order

Contract Overview

Contract Amount: $33,890 ($33.9K)

Contractor: QOL Medical LLC

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-04-02

End Date: 2026-04-07

Contract Duration: 5 days

Daily Burn Rate: $6.8K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: SUCRAID 8500 UNT/ML SOLN

Place of Performance

Location: VERO BEACH, INDIAN RIVER County, FLORIDA, 32963

State: Florida Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $33,890.2 to QOL MEDICAL LLC for work described as: SUCRAID 8500 UNT/ML SOLN Key points: 1. The contract value appears to be a small portion of overall pharmaceutical spending. 2. Competition dynamics for this specific pharmaceutical product are not detailed. 3. The short duration suggests a focused, immediate need. 4. Performance context is limited to the delivery order specifics. 5. This falls within the broader healthcare and pharmaceutical sector.

Value Assessment

Rating: fair

Benchmarking the value of $33,890.2 for a specific pharmaceutical solution is challenging without more context on the quantity and unit price. Compared to larger pharmaceutical contracts, this appears to be a minor award. The firm fixed-price structure provides cost certainty for the government.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. The specific number of bidders is not provided, but the competition type suggests a healthy market for this product.

Taxpayer Impact: Full and open competition generally leads to better price discovery and potentially lower costs for taxpayers.

Public Impact

Veterans receiving care will benefit from the availability of this pharmaceutical solution. The service delivered is the provision of a specific medical solution. The geographic impact is likely limited to the facilities served by the VA in Florida. Workforce implications are minimal, primarily related to logistics and dispensing.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of detailed performance metrics for the delivered solution.
Limited transparency on the specific quantity and unit cost contributing to the total award value.

Positive Signals

Awarded under full and open competition, suggesting market availability.
Firm fixed-price contract provides cost predictability.
Short delivery window indicates responsiveness to an immediate need.

Sector Analysis

The pharmaceutical sector is a significant component of federal healthcare spending. This contract, for a specific solution like SUCRAID, fits within the broader category of pharmaceutical preparation manufacturing. Comparable spending benchmarks would typically involve analyzing the total VA or DoD pharmaceutical spend, which runs into billions annually.

Small Business Impact

There is no indication that this contract was set aside for small businesses, nor are there specific subcontracting requirements mentioned. The award to QOL MEDICAL LLC does not provide information on whether they are a small business themselves. Further analysis would be needed to determine the impact on the small business ecosystem.

Oversight & Accountability

The Department of Veterans Affairs is responsible for oversight of this contract. As a delivery order under a larger contract vehicle (implied), oversight would focus on timely delivery and adherence to the firm fixed-price terms. Transparency is generally available through federal procurement databases.

Related Government Programs

Department of Veterans Affairs Pharmaceutical Contracts
Medical Supplies and Pharmaceuticals
Federal Healthcare Spending

Risk Flags

Short delivery window may strain logistics.
Limited data on unit cost and quantity.
Contractor's federal supply history not detailed.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $33,890.2 to QOL MEDICAL LLC. SUCRAID 8500 UNT/ML SOLN

Who is the contractor on this award?

The obligated recipient is QOL MEDICAL LLC.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $33,890.2.

What is the period of performance?

Start: 2026-04-02. End: 2026-04-07.

What is the specific medical indication and typical usage volume for SUCRAID 8500 UNT/ML SOLN?

SUCRAID (sucrase replacement therapy) is used to treat congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder that affects the digestion of sucrose. Patients with CSID cannot break down sucrose (table sugar) into its simpler components, glucose and fructose, leading to gastrointestinal symptoms such as diarrhea, bloating, abdominal pain, and malnutrition. SUCRAID provides the missing enzyme, sucrase, to aid in the digestion of sucrose. The typical usage volume can vary significantly based on patient age, dietary habits, and the severity of their condition. Dosing is usually adjusted based on the amount of sucrose consumed. The award value of $33,890.2 for a 5-day delivery period suggests either a large quantity for a specific facility or a high unit cost for this specialized medication.

How does the unit cost of SUCRAID 8500 UNT/ML SOLN compare to market rates for similar enzyme replacement therapies?

Determining the precise unit cost from the provided data is not possible without knowing the exact quantity ordered. However, specialized enzyme replacement therapies are often expensive due to the complexity of their development, manufacturing, and the niche patient population they serve. A preliminary search for SUCRAID pricing indicates that it is a high-cost medication. For example, a single bottle (180 mL) can cost several thousand dollars. Without the quantity, a direct comparison to market rates is speculative. The VA's ability to procure this under full and open competition suggests they are leveraging market forces to obtain a competitive price, but the inherent cost of such specialized pharmaceuticals is a significant factor.

What is the track record of QOL MEDICAL LLC in supplying pharmaceuticals to the federal government?

Information regarding QOL MEDICAL LLC's specific track record in supplying pharmaceuticals to the federal government is not detailed in the provided data. A comprehensive analysis would require searching federal procurement databases like SAM.gov or FPDS for past awards to this contractor. This would reveal their history of performance, contract types, agencies served, and any reported issues or successes. Without this historical data, it is difficult to assess their reliability and experience in fulfilling government pharmaceutical needs beyond this single award.

What is the historical spending pattern for SUCRAID 8500 UNT/ML SOLN by the Department of Veterans Affairs?

The provided data only reflects a single, recent delivery order. To understand historical spending patterns for SUCRAID 8500 UNT/ML SOLN by the VA, one would need to query federal procurement databases for all previous contracts and delivery orders issued for this specific National Stock Number (NSN) or product name. This would reveal the frequency of procurement, the total amounts spent over time, the contracting vehicles used (e.g., GSA schedules, other IDIQ contracts), and potentially identify any trends in demand or pricing. Without this historical context, it's impossible to ascertain if this $33.9K award is typical, an outlier, or part of a larger, ongoing procurement strategy.

What are the potential risks associated with a short 5-day delivery window for a pharmaceutical product?

A short 5-day delivery window for a pharmaceutical product like SUCRAID can introduce several risks. Firstly, it necessitates a highly efficient supply chain and logistics process from the contractor to ensure timely delivery. Any disruption, such as transportation delays, inventory shortages, or quality control issues identified late in the process, could lead to non-compliance with the contract terms. Secondly, it may limit the number of potential bidders if only a few companies can reliably meet such a tight deadline, potentially reducing competition. Finally, for critical medications, a delay could impact patient care, although the VA likely has contingency plans for such scenarios. The firm fixed-price nature of the contract means the government is protected from price increases, but not necessarily from delivery failures.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 3405 OCEAN DR, VERO BEACH, FL, 32963

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $33,890

Exercised Options: $33,890

Current Obligation: $33,890

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Parent Contract

Parent Award PIID: 36F79720D0226

IDV Type: FSS

Timeline